Trials / Recruiting
RecruitingNCT06399835
Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis
Comparing Enavogliflozin and Pioglitazone as Add-ons to Metformin With/Without Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Seoul National University Bundang Hospital · Academic / Other
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The current study aimed to thoroughly compare a thiazolidinedione and an sodium-glucose cotransporter-2 (SGLT2) inhibitor regarding various clinical issues including atherosclerosis. Enavogliflozin is compared to Pioglitazone in the glucose-lowering effects of adding to the treatment of patients with type 2 diabetes whose HbA1c levels are not controlled by Metformin with or without DPP-4 inhibitors. Additionally, the study will compare changes in other metabolic or cardiovascular risk factors, such as triglycerides, high density lipoprotein cholesterol (HDLc), uric acid, blood pressure, and inflammatory markers, between the two drugs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enavogliflozin | Enavogliflozin 0.3mg once daily |
| DRUG | Pioglitazone | Pioglitazone 15mg once daily |
Timeline
- Start date
- 2024-02-01
- Primary completion
- 2026-06-01
- Completion
- 2026-12-01
- First posted
- 2024-05-06
- Last updated
- 2024-05-06
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06399835. Inclusion in this directory is not an endorsement.